Cargando…

How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study

OBJECTIVES: Sarcopenia is well known to be associated with mortality, but there is a lack of evidence on the estimates of life expectancy (LE) for sarcopenia in China. This study aims to estimate total life expectancy (TLE) and sarcopenia-specific LE in community-dwelling older Chinese adults with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Bo, Wang, Yujie, Xu, Jixiang, Jiang, Junjia, Yang, Shitong, Chen, Jie, Bao, Zhijun, Gao, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539905/
https://www.ncbi.nlm.nih.gov/pubmed/37780434
http://dx.doi.org/10.3389/fpubh.2023.1203203
_version_ 1785113604672978944
author Ye, Bo
Wang, Yujie
Xu, Jixiang
Jiang, Junjia
Yang, Shitong
Chen, Jie
Bao, Zhijun
Gao, Junling
author_facet Ye, Bo
Wang, Yujie
Xu, Jixiang
Jiang, Junjia
Yang, Shitong
Chen, Jie
Bao, Zhijun
Gao, Junling
author_sort Ye, Bo
collection PubMed
description OBJECTIVES: Sarcopenia is well known to be associated with mortality, but there is a lack of evidence on the estimates of life expectancy (LE) for sarcopenia in China. This study aims to estimate total life expectancy (TLE) and sarcopenia-specific LE in community-dwelling older Chinese adults with and without sarcopenia. METHODS: This study included participants aged 60 years and older who enrolled in the cohort in 2011 and 2013 and at least completed one follow-up until 2015 as part of the China Health and Retirement Longitudinal Study (CHARLS). The criteria for defining sarcopenia were based on the guidelines established by the Asian Working Group on Sarcopenia in 2019. TLE and sarcopenia-specific LE were estimated for the total population and subgroups using continuous-time multistate modeling. RESULTS: A total of 6,029 participants (49.2% women) with an average age of 68.4 (SD: 6.56) years were included in the study. The baseline prevalence of sarcopenia and possible sarcopenia was 19.5 and 44.9%, respectively. We observed that sarcopenia stages naturally deteriorated to worse stages (including death, by 24.4%) and returned to better stages (17.1%) during a median follow-up of 3.92 years (IQR: 2.00 ~ 4.00). The average TLE at the age of 60 was 20.9 [95% CI: 20.2–21.5] years (22.1 [95% CI: 19.6–24.6] for non-sarcopenic older adults, 20.9 [95% CI: 19.5–22.3] for possible sarcopenic, and 18.7 [95% CI: 16.4–21.1] for sarcopenic). Men, former and current smokers, and those living in northwest China had less TLE. Sarcopenic older adults, those with lower education, those who are unmarried, those with agriculture hukou, and those living in rural and northwest China were expected to live fewer years with non-sarcopenia. Sarcopenic older people, men, those with agriculture hukou, and those living in rural and southwest China were expected to live more years with sarcopenia. DISCUSSION: The results improved our understanding of the relationship between sarcopenia and life expectancy. We suggested that targeted strategies should be considered in high-risk populations and underdeveloped regions to prevent sarcopenia and improve non-sarcopenic life years for the older population.
format Online
Article
Text
id pubmed-10539905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105399052023-09-30 How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study Ye, Bo Wang, Yujie Xu, Jixiang Jiang, Junjia Yang, Shitong Chen, Jie Bao, Zhijun Gao, Junling Front Public Health Public Health OBJECTIVES: Sarcopenia is well known to be associated with mortality, but there is a lack of evidence on the estimates of life expectancy (LE) for sarcopenia in China. This study aims to estimate total life expectancy (TLE) and sarcopenia-specific LE in community-dwelling older Chinese adults with and without sarcopenia. METHODS: This study included participants aged 60 years and older who enrolled in the cohort in 2011 and 2013 and at least completed one follow-up until 2015 as part of the China Health and Retirement Longitudinal Study (CHARLS). The criteria for defining sarcopenia were based on the guidelines established by the Asian Working Group on Sarcopenia in 2019. TLE and sarcopenia-specific LE were estimated for the total population and subgroups using continuous-time multistate modeling. RESULTS: A total of 6,029 participants (49.2% women) with an average age of 68.4 (SD: 6.56) years were included in the study. The baseline prevalence of sarcopenia and possible sarcopenia was 19.5 and 44.9%, respectively. We observed that sarcopenia stages naturally deteriorated to worse stages (including death, by 24.4%) and returned to better stages (17.1%) during a median follow-up of 3.92 years (IQR: 2.00 ~ 4.00). The average TLE at the age of 60 was 20.9 [95% CI: 20.2–21.5] years (22.1 [95% CI: 19.6–24.6] for non-sarcopenic older adults, 20.9 [95% CI: 19.5–22.3] for possible sarcopenic, and 18.7 [95% CI: 16.4–21.1] for sarcopenic). Men, former and current smokers, and those living in northwest China had less TLE. Sarcopenic older adults, those with lower education, those who are unmarried, those with agriculture hukou, and those living in rural and northwest China were expected to live fewer years with non-sarcopenia. Sarcopenic older people, men, those with agriculture hukou, and those living in rural and southwest China were expected to live more years with sarcopenia. DISCUSSION: The results improved our understanding of the relationship between sarcopenia and life expectancy. We suggested that targeted strategies should be considered in high-risk populations and underdeveloped regions to prevent sarcopenia and improve non-sarcopenic life years for the older population. Frontiers Media S.A. 2023-09-14 /pmc/articles/PMC10539905/ /pubmed/37780434 http://dx.doi.org/10.3389/fpubh.2023.1203203 Text en Copyright © 2023 Ye, Wang, Xu, Jiang, Yang, Chen, Bao and Gao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Ye, Bo
Wang, Yujie
Xu, Jixiang
Jiang, Junjia
Yang, Shitong
Chen, Jie
Bao, Zhijun
Gao, Junling
How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title_full How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title_fullStr How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title_full_unstemmed How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title_short How long were older people expected to live with or without sarcopenia? Multistate modeling of a national cohort study
title_sort how long were older people expected to live with or without sarcopenia? multistate modeling of a national cohort study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539905/
https://www.ncbi.nlm.nih.gov/pubmed/37780434
http://dx.doi.org/10.3389/fpubh.2023.1203203
work_keys_str_mv AT yebo howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT wangyujie howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT xujixiang howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT jiangjunjia howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT yangshitong howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT chenjie howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT baozhijun howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy
AT gaojunling howlongwereolderpeopleexpectedtolivewithorwithoutsarcopeniamultistatemodelingofanationalcohortstudy